Immunovaccine Researchers to Present Data at Two Upcoming Conferences that Demonstrate the Broad Applicability of the Company’s DepoVax™-based Programs

Print
| Source: Immunovaccine Inc.

Presentation at the 2017 SITC Meeting Will Highlight Preclinical Research on Predicting the Efficacy of Novel Combination Immunotherapies

Researchers at the ReSViNET Conference Will Present Data Focused on Immunovaccine’s Novel RSV Target

HALIFAX, Nova Scotia, Oct. 05, 2017 (GLOBE NEWSWIRE) --  Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that scientific team members will present data at upcoming industry meetings.

Preclinical data to be presented at the 2017 Society for Immunotherapy of Cancer (SITC) annual meeting will examine the characteristics of the tumor microenvironment to assess the potential efficacy of novel combination immunotherapies, including T cell activating therapies formulated with DepoVax-related technology. Details include:

Name:                   “Predicting the efficacy of combination immunotherapy in animal models using tumor microenvironment immune cell profiling.”
Poster Number:     P297
Date:                      Friday, November 10, 2017
Time:                     12:30 to 2 p.m. and 6:30 to 8:00 p.m. ET
Location:               The Gaylord National Hotel & Convention Center in National Harbor, MD

In addition, clinical study investigators will present a poster related to Immunovaccine’s Phase 1 data evaluating its investigational vaccine candidate, DPX-RSV, at the 4th ReSViNET (Respiratory Syncytial Virus Network) Experts’ Meeting taking place in Malaga, Spain from November 29 to December 1, 2017.

This poster is entitled “An RSV Vaccine Based on the Small Hydrophobic Ectodomain Protein Presented with a Novel Lipid-Based Adjuvant is Highly Immunogenic and Safe in Adults.” Researchers will discuss the Company’s novel, proprietary target, the SH ectodomain of the RSV virus, and review the strong safety profile and the highly immunogenic responses from DPX-RSV, which endured up to one year from the initial dosing.

Details on the time and location for the ReSViNET poster viewing will be made available on the Immunovaccine website, under Events, Webcasts and Presentations.

About DepoVax 
DepoVax is Immunovaccine’s proprietary delivery formulation that uses a novel process to present stimulants to the human immune system, and sustain them over time .The technology underlying DepoVax formulations suspends vaccine components in a 100% oil-based diluent that prevents their release at the site of injection. This process forces immune cells to take up these components in an active process, delivering them directly to immune organs such as the lymph nodes. DepoVax formulations have undergone extensive testing in more than 60 preclinical and seven clinical studies. In clinical trials, these formulations have consistently demonstrated the ability to generate robust T and B cell responses, and durable immune responses.

About Immunovaccine
Immunovaccine Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. Immunovaccine develops T cell-activating cancer immunotherapies and other vaccine candidates based on DepoVax, the Company’s patented platform that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. The Company is also exploring additional applications of DepoVax, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. Immunovaccine also has ongoing clinical projects to assess the potential of DepoVax to address malaria and the Zika virus. Connect at www.imvaccine.com.

Immunovaccine Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Contacts for Immunovaccine:

MEDIA 
Mike Beyer, Sam Brown Inc.
T: (312) 961-2502 E: mikebeyer@sambrown.com

INVESTOR RELATIONS
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: info@imvaccine.com    

Patti Bank, Managing Director, Westwicke Partners
O: (415) 513-1284
T: (415) 515-4572 E: patti.bank@westwicke.com